Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products

NCT06887348 is registered in ClinicalTrials.gov with Replimune, Inc. as lead sponsor.

NCT NCT06887348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06887348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
Lead sponsor
Replimune, Inc.
Phase
Observational
Overall status
Recruiting
Start date
December 12, 2025
Completion date
December 31, 2035
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, hepatocellular carcinoma, melanoma, metastatic melanoma